Lessons from rat models of hypertension: From Goldblatt to genetic engineering

Cardiovascular Research

Volumn 39, Issue 1, 1998, Pages 77-88

  Pinto, Yigal M ^a,b   Paul, Martin ^a,b   Ganten, Detlev ^a,b  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Animal models; End organ damage; Genetic; Hypertension

Indexed keywords

ANIMAL MODEL; BLOOD PRESSURE REGULATION; CLINICAL FEATURE; DISEASE COURSE; GENETIC ENGINEERING; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION; REVIEW;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HYPERTENSION; RATS; RATS, INBRED SHR; RATS, INBRED STRAINS;

EID: 0032127132     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00077-7     Document Type: Review

References (107)

1. [1] Massry SG, Smogorzewski M, Hazani E, et al. Influence of Judaism and Jewish physicians on Greek and Byzantine medicine and their contribution to nephrology. Am J Nephrol 1997;17:233-240.
2. [2] Janeway TC. A clinical study of hypertensive cardiovascular disease. Arch Intern Med (Chicago) 1913;12:755.
3. [3] Goldblatt H, Lynch J, Hanzal RF, et al. Studies on experimental hypertension. 1. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934;59:347-379.
4. [4] Wilson, P.W.F., Kannel, W.B. In: Laragh JH, Brenner BM. editors, Hypertension: pathophysiology, diagnosis and management. New York: Raven Press, 2nd edition, 1995.
5. [5] Laragh JH, Resnick LM. Recognizing and treating two types of long-term vasoconstriction in hypertension. Kidney Int 1988;25:S162-S174.
6. [6] Ganten, D., de Jong, W. In: Birkenhager WH, Reid JT, editors. Handbook of hypertension, Vol. 16: Experimental and genetic models of hypertension. Amsterdam:Elsevier, 1994.
7. [7] Okakomoto Aoki K. Development of a strain of spontaneously hypertensive rat. Jap Circ J 1963;27:282-293.
8. [8] Yamori, Y. Development of the spontaneoulsy hypertensive rat (SHR) the stroke prone hypertensive SHR (SHRSP) and their various substrain models for hypertension-related cardiovascular diseases. in: Ganten D, de Jong W (volume editors) Birkenhager WH, Reid JT (series editors). Handbook of hypertension, Volume 16: Experimental and genetic models of hypertension. Amsterdam:Elsevier, 1994.
9. [9] Aitman TJ, Gotoda T, Evans AL, et al. Syndrome X genes: Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats. Nat Genet 1997;16(2):197-201.
10. [10] Kren V, Pravenec M, Lu S, et al. Genetic isolation of a region of chromosome 8 that exerts major effects on blood pressure and cardiac mass in the spontaneously hypertensive rat. J Clin Invest 1997;99(4):577-581.
11. [11] Kapuscinski M, Charchar F, Innes B, et al. Nerve growth factor gene and hypertension in spontaneously hypertensive rats. J Hypertens 1996;14(2):191-197.
12. [12] Kreutz R, Struk B, Rubattu S, et al. Role of the alpha, beta, and gamma subunits of epithelial sodium channel in a model of polygenic hypertension. Hypertension 1997;29(1 Pt 1):131-136.
13. [13] Cerqua S, Samaan A. Cure of experimental renal hypertension. Clin Sci 1939;40:113-118.
14. [14] Swales JD, Tange JD. The influence of acute sodium depletion on experimental hypertension in the rat. J Lab Clin Med 1971;78(3):369-379.
15. [15] Koletsky S, Pavlicko KM, Rivera Velez JM. Renin angiotensin activity in hypertensive rats with a single ischemic kidney. Lab Invest 1971;24(1):41-44.
16. [16] Brunner HR, Kirshman JD, Sealey JE, et al. Hypertension of renal origin: evidence for two different mechanisms. Science 1971;174(16):1344-1346.
17. [17] Gomez-Sanchez EP, Zhou M, Gomez-Sanchez CE. Mineralocorticoids, salt and high blood pressure. Steroids 1996;61:184-188.
18. [18] Meneely GR, Ball COT. Experimental epidemiology of chronic sodium chloride toxicity and the protective effect of potassium chloride. Am J Med 1958;25:713.
19. [19] Rapp JP. Dahl salt susceptible and salt resistant rats. Hypertension 1982;4:753-763.
20. [20] Deng Y, Rapp JP. Cosegregation of blood pressure with angiotensin converting enzyme and atrial natriuretic peptide receptor genes using Dahl salt sensitive rats. Nat Genet 1992;1:267-272.
21. [21] Langheinrich M, Lee MA, Bohm M, et al. The hypertensive Ren 2 transgenic rat TGR (mREN2)27 in hypertension research. Characteristics and functional aspects. Am J Hypertens 1996;9:506-512.
22. [22] Whitworth CE, Fleming S, Cumming AD, et al. Spontaneous development of malignant phase hypertension in transgenic Ren 2 rats. Kidney Int 1994;46:1528-1532.
23. [23] Conrad CH, Brooks WW, Robinson KG, et al. Impaired myocardial function in spontaneously hypertensive rats with heart failure. Am J Physiol 1991;260:H136-H145.
24. [24] Pfeffer JM, Pfeffer MA, Fishbein MC, et al. Cardiac function and morphology with aging in the spontaneously hypertensive rat. Am J Physiol 1979;237:H461-H468.
25. [25] Feld LB, van Liew JB, Galaske RG, et al. Selectivity of renal injury and proteinuria in the spontaneously hypertensive rat. Kidney Int 1977;12:332-343.
26. [26] Komatsu K, Frohlich ED, Ono H, et al. Glomerular dynamics and morphology of aged SHR. Hypertension, 1995;25:207-213.
27. [27] Luscher TF, Aarhus LL, Vanhoutte PM. Indomethacin improves the impaired endothelium dependent relaxations in small mesenteric arteries of the spontaneously hypertensive rat. Am J Hypertens 1990;3:55-58.
28. [28] Besse S, Robert V, Assayag P, et al. Nonsynchronous changes in myocardial collagen mRNA and protein during aging: effect of DOCA salt hypertension. Am J Physiol 1994;267:H2237-H2244.
29. [29] Lafferty HM, Garcia DL, Rennke HG, et al. Anemia ameliorates progressive renal injury in experimental DOCA salt hypertension. J Am Soc Nephrol 1991;1:1180-1185.
30. [30] Kirchner KA, Scanlon Jr. PH, Dzielak DJ, et al. Endothelium derived relaxing factor responses in Doca salt hypertensive rats. Am J Physiol 1993;265:R568-R572.
31. [31] Linz W, Schoelkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypert (A) 1989;11:1325-1350.
32. [32] Eleftheriades EG, Durand JB, Ferguson AG, et al. Regulation of procollagen metabolism in the pressure overloaded rat heart. J Clin Invest 1993;91:1113-1122.
33. [33] Blantz RC, Gabbai F, Gushwa LC, et al. The influence of concomitant experimental hypertension and glomerulonephritis. Kidney Int 1987;32:652-663.
34. [34] Buikema H, van Gilst WH, van Veldhuisen DJ, et al. Endothelium dependent relaxation in two different models of chronic heart failure and the effect of ibopamine. Cardiov Res 1993;27:2118-2124.
35. [35] Pinto YM, Buikema H, van Gilst WH, et al. Cardiac and vascular dysfunction is more severe in hypertensive transgenic rats harboring the mouse Ren 2 gene than in spontaneously hypertensive rats. J Mol Med 1997;75:371-377.
36. [36] Chung O, Schips T, Rohmeiss P, et al. Protein excretion and renal adaptation of transgenic mRen2 rats to changing oral sodium loads. J Hypertens 1993;11:S188-S189.
37. [37] Pfeffer MA, Pfeffer J, Mirsky I, et al. Cardiac hypertrophy and performance of Dahl hypertensive rats on graded salt diets. Hypertension, 1984;6:475-481.
38. [38] Inoko M, Kihara Y, Sasayama S. Neurohumoral factors during transition from left ventricular hypertrophy to failure in Dahl salt sensitive rats. Biochem Biophys Res Commun 1995;206:814-820.
39. [39] Sustarsik DL, McPartland RP, Rapp JP. Developmental patterns of blood pressure and urinary protein, kallikrein and prostaglandin E2 in Dahl salt hypertension susceptible rats. J Lab Clin Med 1981;98:599-606.
40. [40] Sterzel RB, Luft FC, Gao Y, et al. Renal disease and the development of hypertension in salt sensitive Dahl rats. Kidney Int 1988;33:1119-1129.
41. [41] Luscher TF, Raij L, Vanhoutte PM. Endothelium dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension 1987;9:157-163.
42. [42] Mantero F, Nussdorfer GG, Robba C, et al. Evidence for mineralocorticoid activity in the Milan Hypertensive strain of rats. J Hypertens 1983;1:150-152.
43. [43] Brandis A, Bianchi G, Reale E, et al. Age dependent glomerulosclerosis and proteinuria occurring in rats of the Milan normotensive strain and not in rats of the Milan hypertensive strain. Lab Invest 1986;55:234-243.
44. [44] Limas C, Westrum B, Limas CJ. Comparative effects of hydralazine and captopril on the cardiovascular changes in spontaneously hypertensive rats. Am J Pathol 1984;117:360-371.
45. [45] Takenaka T, Asano M, Shiono K, et al. Cardiovascular pharmacology of nicardipine in animals. Br J Clin Pharmacol 1985;20:7S-22S.
46. [46] Wada T, Sanada T, Ojima M, et al. Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV 116) and other classes of antihypertensive drugs in spontaneously hypertensive rats. Hypertens Res 1996;19:247-254.
47. [47] Ieki K, Yazaki Y, Yamaoki K. Effect of long term treatment with beta blocker on cardiac hypertrophy in SHR. J Mol Cell Cardiol 1989;21:113-119.
48. [48] Takeda K, Nakagawa Y, Hashimoto T, et al. Effects of several beta blocking agents on the development of hypertension in spontaneously hypertensive rats. Jpn J Pharmacol 1979;29:171-178.
49. [49] Komatsu K, Frohlich ED, Ono H, et al. Glomerular dynamics and morphology of aged SHR. Hypertension 1995;25:207-213.
50. [50] Dohi Y, Thiel MA, Buehler FR, et al. Activation of endothelial 1 arginine pathway in resistance arteries: effect of age and hypertension. Hypertension 1990;15:170-179.
51. [51] Karam H, Heudes D, Bruneval P, et al. Endothelin antagonism in end organ damage of spontaneously hypertensive rats. Comparison with angiotensin converting enzyme inhibition and calcium antagonism. Hypertension 1996;28:379-385.
52. [52] Pfeffer JM, Pfeffer MA, Mirsky I, et al. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci USA 1982;79:3310-3314.
53. [53] Stasch JP, Kazda S, Hirth C, et al. Role of nisoldipine on blood pressure, cardiac hypertrophy, and atrial natriuretic peptides in spontaneously hypertensive rats. Hypertension 1987;10:303-307.
54. [54] Benetos A, Poitevin P, Prost PL, et al. Life survival and cardiovascular structures following selective beta blockade in spontaneously hypertensive rats. Am J Hypertens 1994;7:186-192.
55. [55] Lee RM, Tsoporis J, Wang RR. Influence of chronic nadolol treatment on blood pressure and vascular changes in spontaneously hypertensive rats. Can J Physiol Pharmacol 1992;70:1261-1270.
56. [56] Numabe A, Uehara Y, Hirawa N, et al. Effects of thiazide diuretic on vascular eicosanoid system of spontaneously hypertensive rats. J Hypertens 1989;7:493-499.
57. [57] Clozel M, Kuhn H, Hefti F. Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension 1990;6:541-543.
58. [58] Kohara K, Mikami H, Okuda N, et al. Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat. Hypertension 1993;21:975-979.
59. [59] Aono J, Koga T, Yamazaki T, et al. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC 838) in several hypertensive models of rats: comparison with captopril. Arch Int Pharmacodyn Ther 1988;292:203-222.
60. [60] Li JS, Sventek P, Schiffrin EL. Effect of antihypertensive treatment and N omega nitro L arginine methyl ester on cardiovascular structure in deoxycorticosterone acetate salt hypertensive rats. J Hypertens 1996;14:1331-1339.
61. [61] Fujita K, Matsumura Y, Miyazaki Y, et al. Effects of the endothelin ETA receptor antagonist FR139317 on development of hypertension and cardiovascular hypertrophy in deoxycorticosterone acetate salt hypertensive rats. Jpn J Pharmacol 1996;70:313-319.
62. [62] Cabral AM, Carvalhinho FB, Vasquez EC, et al. Effects of chlorthalidone on ventricular hypertrophy in deoxycorticosterone acetate salt hypertensive rats. Hypertension 1994;23:I180-I184.
63. [63] Anderson PG, Bishop SP, Digerness SB. Coronary vascular function and morphology in hydralazine treated DOCA salt rats. J Mol Cell Cardiol 1988;20:955-967.
64. [64] Michel JB. Relationship between decrease in afterload and beneficial effects of ACE inhibitors in experimental cardiac hypertrophy and congestive heart failure. Eur Heart J 1990;11:17-26.
65. [65] Bakris GL. Renal effects of calcium antagonists in diabetes mellitus. An overview of studies in animal models and in humans. Am J Hypertens 1991;4:487S-493S.
66. [66] Hirata Y, Hayakawa H, Kakoki M, et al. Nitric oxide release from kidneys of hypertensive rats treated with imidapril. Hypertension 1996;27:672-678.
67. [67] Bouvier M, de Champlain J. Effects of acute and chronic administration of sotalol on the blood pressure and the sympathoadrenal activity of anesthetized deoxycorticosterone acetate salt hypertensive rats. Can J Physiol Pharmacol 1986;64:1164-1169.
68. [68] Li JS, Knafo L, Turgeon A, et al. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol 1996;271:H88-H93.
69. [69] Smith SH, Kramer MF, Reis I, et al. Regional changes in creatine kinase and myocyte size in hypertensive and nonhypertensive cardiac hypertrophy. Circ Res 1990;67:1334-1344.
70. [70] Kobayashi K, Tarazi RC. The chronic effect of nitrendipine on heart and regional blood flow in renovascular hypertensive rats. Jpn Circ J 1987;51:1027-1034.
71. [71] Lindpaintner K, Sen S. Role of beta 1 adrenoceptors in hypertensive cardiac hypertrophy. J Hypertens 1987;5:663-669.
72. [72] Wang YX, Gavras I, Wierzba T, et al. Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin II receptor antagonist, and an angiotensin converting enzyme inhibitor in conscious renovascular hypertensive rats. J Lab Clin Med 1992;119:267-272.
73. [73] Linz W, Schölkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hyper A 1989;11:1325-1350.
74. [74] Ohta K, Kim S, Wanibuchi H, et al. Contribution of local renin angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodeling in TGR (mRen2)27 transgenic rats. Circulation 1996;94:785-791.
75. [75] Pinto YM, Teisman AC, van Gilst WH, et al. Different effects of Quinapril, Losartan and Carvedilol on vascular function in the Ren-2 transgenic rat (abstract). J Hypertens 1996;14:S24.
76. [76] Fernandez D, Bolli P, Snedden W, et al. Modulation of left ventricular hypertrophy by dietary salt and inhibition of angiotensin converting enzyme. J Hypertens 1988;6(Suppl):S145-S147.
77. [77] Uehara Y, Takada S, Hirawa N, et al. Vasoconstrictors and renal protection induced by beta 1 selective adrenoceptor antagonist bisoprolol. J Cardiovasc Pharmacol 1994;23:897-906.
78. [78] Hirawa N, Uehara Y, Kawabata Y, et al. Mechanistic analysis of renal protection by angiotensin converting enzyme inhibitor in Dahl salt sensitive rats. J Hypertens 1994;12:909-918.
79. [79] McCaughran Jr. JA, Juno CJ. Calcium channel blockade with verapamil. Effects on blood pressure, renal, and myocardial adrenergic, cholinergic, and calcium channel receptors in inbred Dahl hypertension sensitive (S/JR) and hypertension resistant (R/JR) rats. Am J Hypertens 1988;1:255S-262S.
80. [80] O'Donnell MP, Kasiske BL, Katz SA, et al. Lovastatin but not enalapril reduces glomerular injury in Dahl salt sensitive rats. Hypertension 1992;20:651-658.
81. [81] Tolins JP, Raij L. Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 1990;16:452-461.
82. [82] Uehara Y, Numabe A, Hirawa N, et al. Antihypertensive effects of cicletanine and renal protection in Dahl salt sensitive rats. J Hypertens 1991;9:719-728.
83. [83] Doucet J, Gonzalez W, Michel JB. Endothelin antagonists in salt dependent hypertension associated with renal insufficiency. J Cardiovasc Pharmacol 1996;27:643-651.
84. [84] Luscher TF, Vanhoutte PM, Raij L, et al. Antihypertensive treatment normalizes decreased endothelium dependent relaxations in rats with salt induced hypertension. Hypertension 1987;9:III193-III177.
85. [85] Sen S, Tarazi RC, Bumpus FM. Cardiac hypertrophy and antihypertensive therapy. Cardiovasc Res 1977;11(5):427-433.
86. [86] Lundin SA, Hallback Nordlander MI. Regression of structural cardiovascular changes by antihypertensive therapy in spontaneously hypertensive rats. J Hypertens 1984;2(1):11-18.
87. [87] Ljung B, Ablad B, Drews L, et al. Antihypertensive effect of metoprolol in spontaneously hypertensive rats. Clin Sci Mol Med 1976;3:443S-445S.
88. [88] Motz W, Strauer BE. Regression of structural cardiovascular changes by antihypertensive therapy. Hypertension 1984;6:III133-III139.
89. [89] Kawano K, Hirashima T, Mori S, et al. Spontaneous long term hyperglycemic rat with diabetic complications. Otsuka Long Evans Tokushima Fatty (OLETF) strain. Diabetes 1992;41:1422-1428.
90. [90] Yagi K, Kim S, Wanibuchi H, et al. Characteristics of diabetes, blood pressure, and cardiac and renal complications in Otsuka Long Evans Tokushima Fatty rats. Hypertension 1997;29:728-735.
91. [91] van den Maagdenberg AM, Hofker MH, Krimpenfort PJ, et al. Transgenic mice carrying the apolipoprotein E3 Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993;268:10540-10545.
92. [92] Frank RK, Newman JA, Noll SL, et al. The incidence of perirenal hemorrhage syndrome in six flocks of market turkey toms. Avian Dis 1990;34:824-832.
93. [93] Krista LM, Mora EC, McDaniel GR. A comparison between aortic lumen surfaces of hypertensive and hypotensive turkeys. Poult Sci 1979;58:738-744.
94. [94] Krista LM, McDaniel GR, Mora EC, et al. Histological evaluation of the vascular system for the severity of atherosclerosis in hyper and hypotensive male and female turkeys: comparison between young and aged turkeys. Poult Sci 1987;66:1033-1044.
95. [95] Knorr A, Garthoff B, Kazda S, et al. Effects of different antihypertensive drug classes on survival in animal models. J Cardiovasc Pharmacol 1991;17:S94-S100.
96. [96] Franz WM, Mueller OJ, Hartong R, et al. Transgenic animal models: new avenues in cardiovascular physiology. J Mol Med 1997;75:115-129.
97. [97] Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren 2 gene. Nature 1990;344:541-544.
98. [98] Lee MA, Bohm M, Paul M, et al. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol 1996;270:E919-E929.
99. [99] Okhubo H, Kawakami H, Kakehi Y, et al. Generation of transgenic mice with elevated bloodpressure by introduction of the rat renin and angiotensinogen genes. Proc Nat Acad Sci 1990;87:5153-5157.
100. [100] Bohlender J, Fukamizu A, Lippoldt A, et al. High human renin hypertension in transgenic rats. Hypertension 1997;29:428-434.
101. [101] John SW, Krege JH, Oliver PM, et al. Genetic decreases in atrial natriuretic peptide and salt sensitive hypertension. Science 1995;267:679-681.
102. [102] Lopez MJ, Wong SK, Kishimoto I, et al. Salt resistant hypertension in mice lacking the guanylyl cyclase A receptor for atrial natriuretic peptide. Nature 1995;378:65-68.
103. [103] Wiesel P, Mazzolai L, Nussberger J, et al. Two kidney, one clip and one kidney, one clip hypertension in mice. Hypertension 1997;29:1025-1030.
104. [104] Harats D, Kuriihara H, Belloni P, et al. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin 1 promoter. J Clin Invest 1995;95:1335-1344.
105. [105] Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline responsive promoters. Proc Natl Acad Sci USA 1992;89:5547-5551.
106. [106] Furt PA, St. Onge L, Boger H, et al. Temporal control of gene expression in transgenic mice by a tetracycline responsive promoter. Proc Natl Acad Sci USA 1994;91:9302-9306.
107. [107] Brown DM, Provoost AP, Daly MJ, Lander ES, Jacob HJ. Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded rat. Nat Genet 1996;12:44-51.